Enliven Therapeutics公司宣布,将在2026年欧洲血液学协会(EHA)大会上进行一项口头报告,重点展示其候选药物ELVN-001用于治疗慢性粒细胞白血病(CML)的额外积极1期临床试验数据。此次报告将进一步呈现该药物在早期临床研究中的积极结果。
Enliven Therapeutics公司宣布,将在2026年欧洲血液学协会(EHA)大会上进行一项口头报告,重点展示其候选药物ELVN-001用于治疗慢性粒细胞白血病(CML)的额外积极1期临床试验数据。此次报告将进一步呈现该药物在早期临床研究中的积极结果。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.